8-K
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
8-K
CapsoVision Announces $18 Million Registered Direct Offering of Common Stock
8-K
CapsoVision, Inc. Enters into $100 Million At-the-Market Equity Offering Program
8-K
CapsoVision Reports Second Quarter 2026 Financial Results
8-K
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
8-K
CapsoVision, Inc. Announces Results of 2026 Annual Meeting of Stockholders
